BPC-157 for Knees and Shoulders: What the Research Actually Covers

The short answer: almost everything known about BPC-157 for tendons, ligaments and muscles comes from rats, and most of it from one lab in Croatia. In people, there's one small knee-pain chart review with no comparison group. There is no published study of BPC-157 for a meniscus tear, a rotator cuff or knee arthritis, in animals or in people.

That doesn't mean it does nothing. It means nobody has tested it in a way that would tell you. The first two randomized human trials in muscle and tendon injuries are only now registered, and neither has results. One of them is in shoulders. The other only enrolls people up to age 45.

Status as of October 24, 2026: BPC-157 is not FDA-approved for any use, and no approved product contains it anywhere. It is not on the list of substances pharmacies may compound from. An FDA advisory panel voted 8-6 in July to recommend adding it, which is advisory only. A proposed "interim access" policy is still under White House review. This post describes what studies measured. It isn't medical advice. If your knee or shoulder hurts, ask your doctor or orthopedist.

Updated October 2026. PubMed and ClinicalTrials.gov were searched on October 24, 2026.

Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.

Lots of animal work, very little human work, and no finished randomized trials. Here's how the evidence stacks up.

Sources: Vasireddi et al., HSS Journal, 2025, Poolton et al., Acta Orthop Belg, Oct 2026, ClinicalTrials.gov, searched October 24, 2026.

A PubMed search on October 24, 2026 that combined BPC-157 with clinical-trial or randomized-trial filters returned zero records.

They cut a tendon, ligament or muscle in rats, gave BPC-157 or saline, and compared the two groups over days to weeks. The main ones:

Two caveats matter. These are clean surgical cuts in healthy rats, not a worn meniscus or an aging rotator cuff in a 60-year-old. And FDA's own reviewers summed up this body of work in one line: BPC-157 "promotes healing of transected tendons in rodents" (FDA briefing document, July 2026). Rodents is the key word.

Mostly one group. Of 222 PubMed records mentioning BPC-157 on October 24, 2026, 171 list Predrag Sikiric of the University of Zagreb as an author. That's about 77%.

That alone doesn't make the work wrong. But it hasn't been widely repeated by outside labs. An investigation by Undark, co-published by STAT, reported that Sikiric is "named on BPC-157-related patent applications dating back to at least 1989," and that those conflicts "were not disclosed on any of the team's published papers that Undark reviewed" (STAT/Undark, Feb 3, 2026).

When an outside team did test it, the signal was weaker. In a 2026 study from Istanbul, 32 rats had their Achilles tendons cut and repaired. The BPC-157 group "showed numerically lower scores without reaching statistical significance" on tissue scores, and its strength gain wasn't statistically significant either. TB-500 did better on those measures, and combining the two "did not confer additional benefits" (Biçer et al., Jt Dis Relat Surg, July 2026). One study, still in rats. But it's the kind of check the field has mostly lacked. For how the two peptides differ, see BPC-157 vs TB-500.

One study. It's small, looks backward, and has no comparison group.

A primary care clinic in Orlando reviewed its charts from 2019 to 2020 for patients given BPC-157 directly into the knee joint, alone or with another peptide. Of 17 patients, 16 were reached by phone months later and asked to rate their pain. Among the 12 who got BPC-157 alone, 11 said their knee pain had improved significantly. The authors note "no specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living" (Lee & Padgett, Altern Ther Health Med, 2021). A later review summarized the same study as 7 of 12 reporting relief lasting over six months (HSS Journal).

Why that isn't proof:

The newest systematic review, published October 8, 2026, found three human studies of BPC-157 for any use, 30 people in all. It rated all three "of poor methodological quality" and the overall certainty of evidence "very low" (Poolton et al., Acta Orthop Belg).

No. A PubMed search on October 24, 2026 found no study of BPC-157 and the meniscus in animals or people. The word shows up only in the knee-pain chart review, as one of many possible causes of knee pain, and in a review's search terms.

So any claim about BPC-157 and meniscus tears goes beyond the published evidence. If you have a meniscus tear, an orthopedist can walk you through what the evidence supports for your type of tear.

There's no published shoulder study in animals or people. There is one registered trial, and it hasn't started.

The University of Arkansas for Medical Sciences registered a small randomized, double-blind trial in September 2026. Adults having arthroscopic rotator cuff repair will get BPC-157 or saline, alongside standard rehab, with MRI checks on the tendon afterward. It's listed as not yet recruiting, with an estimated start of January 2027 and about 30 people (NCT07803250). The trial's own description says BPC-157 "has not yet been studied in formal human clinical trials."

There's no published study in people for any of the three, and no animal study of wear-and-tear knee arthritis either.

The only rat "arthritis" work is in adjuvant arthritis, an immune-triggered model that's closer to inflammatory arthritis than to osteoarthritis, the wear-and-tear kind (Sikiric et al., 1997). PubMed returned no BPC-157 studies on plantar fascia, and nothing on the spine for back pain.

Not in people yet. The Arkansas rotator cuff trial is the first registered test after surgery, and it won't start until 2027. In rats, the 2006 tendon-to-bone study is the closest thing to a surgical repair model (Krivic et al.). Anything you do around a surgery is a conversation for your surgeon.

Two are registered in muscle or tendon injury. Neither has results, and none is in knee, meniscus or arthritis.

The 2015 safety trial matters for a different reason. FDA's reviewers wrote that "there are no results posted, and we were unable to find an associated published study" (FDA briefing). Undark reported that Croatian records list Sikiric as an owner of the company that sponsored it (STAT/Undark).

Note the age cap on the hamstring trial. If you're 55, even the best-run of these trials won't tell you much about tendons your age.

It isn't approved, and pharmacies can't currently compound it under FDA's lists. That hasn't changed since the summer.

Tendonitis was one of the uses BPC-157 was nominated for. FDA declined to evaluate it, saying the nomination "did not include sufficient information" and that "FDA did not identify clinical studies using BPC-157 in these populations" (FDA briefing). The advisory committee still voted 8-6, with one abstention, to recommend adding BPC-157 to the compounding list. Those votes "are advisory only," and FDA would still need to accept them, propose a rule and finalize it (Holland & Knight, Oct 16, 2026).

The "Interim Access Policy for Compounding Using Certain Peptides" was still listed as pending review at the White House budget office on October 24, 2026 (OIRA). Its text and covered peptides aren't public. Every step is on the compounding status tracker, and what each route costs is in what BPC-157 actually costs.

Nobody knows the side-effect profile in people, because it's never been measured in a proper trial.

The 2025 orthopedic review found "no clinical safety data" (HSS Journal). The small human studies reported no serious problems, but FDA's reviewers noted they "were of short duration, had small sample sizes" and gave limited safety information. FDA also flagged a possible risk of immune reactions for some routes, since peptides can trigger them (FDA briefing).

FDA's adverse event database had three reports through December 2025. One involved a 40-year-old woman using a "research purposes only" product combining BPC-157 and TB-500 "for 'joint healing and wound healing support.'" She developed darkened skin and gums, and it happened again when she restarted. Because the product had two peptides, FDA said it couldn't pin it on BPC-157 (FDA briefing). One report is not a pattern. It's a reminder that the absence of data isn't the same as safety.

If you're on blood thinners, steroids or other medicines, or you've had cancer, that's a conversation to have with your doctor before anything new.

Yes. WADA's 2026 Prohibited List names BPC-157 under S0, non-approved substances, banned at all times (WADA). That applies to any athlete under anti-doping rules, including masters competitors.

On the evidence that exists, nobody can say. The rat studies are consistent but come mostly from one lab. The one knee study in people can't separate the peptide from placebo. A UCLA orthopedic review published in August concluded these peptides "should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care" (Tewari et al., Am J Sports Med, 2026).

For comparison, here's what has strong evidence for knee osteoarthritis. The American Academy of Orthopaedic Surgeons gives its strongest rating to exercise, including supervised physical therapy, self-management and education programs, and topical or oral anti-inflammatories when they're safe for you (AAOS guideline, 2021). That's context, not a plan. Your doctor or orthopedist can tell you which of those fits your knee, your shoulder and your health history.

The Arkansas trial is the one to watch. If it runs as registered, it will be the first placebo-controlled look at BPC-157 in an injured human tendon. For the bigger picture on why so many peptides have animal data and no trials, see a doctor told 8 million people peptides are hype.

Next step: see the vendors I use and how they score on testing, reviews and support. Code BHN40 takes 40% off.

The vendor links on that page are affiliate links. If you buy through them, BHN earns a commission.

Want the one-page version of what's approved, what's legal and what's actually been tested? Get the free BHN cheat sheet.